Horizon Therapeutics Reports Q4 Results, Beats Revenue Target
On Wednesday morning, Horizon Therapeutics (NASDAQ: HZNP) announced its fourth-quarter and full-year financial results. Thanks to strong sales of its top drug, a gout treatment known as Krystexxa, the company beat both its revenue and earnings estimates.
Fourth-quarter revenue came in at $363.5 million, which is up 2.3% from last year. The biggest revenue driver for the company came from its orphan and rheumatology department, which brought in $269.8 million in Q4 2019, up 13.6% from Q4 2018. Sales of Krystexxa came in at $110.7 million, a 33% increase since last year. Horizon's second top-performing drug, Ravicti, is used to help prevent ammonia buildup in patients with urea cycle disorder. The drug's sales came in at $68.5 million for the quarter, a 14% increase from Q4 2018.
Image source: Getty Images.
Source Fool.com
